Measuring Friedreich ataxia: Complementary features of examination and performance measures

Neurology

Volumn 66, Issue 11, 2006, Pages 1711-1716

  Lynch, D R ^a,b   Farmer, J M ^a   Tsou, A Y ^a   Perlman, S ^c   Subramony, S H ^d   Gomez, C M ^e   Ashizawa, T ^f   Wilmot, G R ^g   Wilson, R B ^a   Balcer, L J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^g EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; AGE; ARTICLE; CLINICAL FEATURE; CONSTRUCT VALIDITY; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FRIEDREICH ATAXIA; FRIEDREICH ATAXIA RATING SCALE; FUNCTIONAL DISEASE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PERFORMANCE; PRIORITY JOURNAL; RATING SCALE; SHORT FORM 36; TRINUCLEOTIDE REPEAT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DISABILITY EVALUATION; FEMALE; FRIEDREICH ATAXIA; GAIT ATAXIA; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICAL EXAMINATION; PROGNOSIS; PSYCHOMOTOR PERFORMANCE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 33745659239     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000218155.46739.90     Document Type: Article

References (13)

1. Lynch DR, Farmer JM, Balcer LJ, Wilson RB. Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch Neurol 2002;59:743-747.
2. Durr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med 1996;335:1169-1175.
3. Delatycki MB, Paris DB, Gardner RJ, et al. Clinical and genetic study of Friedreich ataxia in an Australian population. Am J Med Genet 1999;87:168-174.
4. Campuzano V, Montermini L, Molto MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996;271:1423-1427.
5. Cossee M, Durr A, Schmitt M, et al. Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 1999;45:200-206.
6. Subramony SH, May W, Lynch D, et al. Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 2005;64:1261-1262.
7. Cutter GE, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122:871-882.
8. Balcer LJ, Baier ML, Cohen JA, et al. Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology 2003;61:1367-1373.
9. Lynch DR, Farmer JM, Wilson RL, Balcer LJ. Performance measures in Friedreich ataxia: potential utility as clinical outcome tools. Mov Disord 2005;20:777-782.
10. Lynch DR, Farmer JM, Rochestie D, Balcer LJ. Contrast letter acuity as a measure of visual dysfunction in patients with Friedreich ataxia. J Neuroophthalmol 2002;22:270-274.
11. Ritvo PG, Fischer JS, Miller DM, et al. Multiple Sclerosis Quality of Life Inventory (MSQLI): a user's manual. New York: National Multiple Sclerosis Society, 1997.
12. Balcer LJ, Baier ML, Pelak VS, et al. New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis. Mult Scler 2000;6:163-171.
13. Bryden PJ, Roy EA. Unimanual performance across the age span. Brain Cogn 2005;57:26-29.